The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value

Cardiology Journal

Volumn 15, Issue 4, 2008, Pages 357-364

  Lewandowski, Maciej ^a   Kornacewicz Jach, Zdzisława ^a   Millo, Barbara ^a   Zielonka, Joanna ^a   Czechowska, Małgorzata ^a   Kaliszczak, Robert ^a   Płońska, Edyta ^a   Goracy, Jarosław ^a   Kaźmierczak, Jarosław ^a   Naruszewicz, Marek ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Acute coronary syndrome; Atorvastatin; CRP; IL 6; Inflammation; MCP 1; Restenosis; TNF

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; ANGIOCARDIOGRAPHY; BLOOD; COMPARATIVE STUDY; DRUG ADMINISTRATION; FOLLOW UP; HOSPITALIZATION; MIDDLE AGED; NONPARAMETRIC TEST; PROBABILITY; RISK ASSESSMENT; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CHEMOKINE CCL2; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROBABILITY; PYRROLES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 55249115159     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Liuzzo G, Biasucci LM, Galimore JR et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med, 1994; 331: 417-424.
2. Jialal J, Stein D, Belis D et al. Effects of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation, 2001; 103: 1933-1935.
3. Nissen SE, Tuzcu EM, Schoenhagen P et al. REVERSAL investigators. Statin therapy, LDL-cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med, 2005; 352: 29-38.
4. Kinlay S, Timms T, Clark M et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol, 2002; 89: 1205-1207.
5. Kinlay S, Schwartz GG, Olsson AG et al. High dose Atorvastatin enhances the decline in inflammatory markers with acute coronary syndrome in the MIRACL study. Circulation, 2003; 108: 1560-1566.
6. Balbay Y, Tikiz H, Baptiste RJ et al. Circulating IL-1 beta, IL-6, TNF alpha and soluble ICAM-1 in patients witch chronic stable angina and myocardial infarction. Angiology, 2001; 52: 109-114.
7. Pasceri V, Chang J, Willerson JT et al. Modulation of CRP-mediated MCP-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation, 2001; 103: 2531-2534.
8. Mazzone A, de Servi S, Mazzucchelli I et al. Increased concentrations of inflammatory mediators in unstable angina: correlation with serum troponin T. Heart, 2001; 85: 571-575.
9. Cannon CP, Braunwald E, Mc Cabe C et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-TIMI 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Eng J Med, 2004; 350: 1495-1904.
10. Nissen SE. High-dose statins in acute coronary syndromes: Not just lipid levels. JAMA, 2004; 292: 1365-1367.
11. Ridker PM, Cannon CP, Morrow D et al. PROVE IT-TIMI 22 Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med, 2005; 352: 20-28.
12. de Lemos JA, Blazing MA, Wiviott SD. A to Z Investigators. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z Trial. JAMA, 2004; 292: 1307-1316.
13. Toutozas K, Colombo A, Stefanadis Ch. Inflammation and restenosis after percutaneous coronary intervention. Eur Heart J, 2004; 25: 1679-1687.
14. Hokimoto S, Ogawa H, Saito T et al. Increased plasma antigen levels of monocyte chemoattractant protein-1 in patients with restenosis after percutaneous transluminal coronary angioplasty. Jpn Circ J, 2000; 64: 831-834.
15. Ikeda U, Matsui K, Murakami Y, Shimada K. Monocyte chemoattractant protein-1 and coronary artery disease. Clin Cardiol. 2002; 25: 143-147.
16. Macin SM, Perna ER, Parias EF et al. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. Am Heart J. 2005; 149: 451-457.
17. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet, 2001; 357: 995-1001.
18. Ostadal P, Alan D, Hajek P et al. Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial) [ISRCTN81331696]. Curr Control Trials Cardiovasc Med, 2005; 6: 4.
19. Brueckmann M, Bertsch T, Lang S et al. Time course of systemic markers of inflammation in patients with ACS. Clin Chem Lab Med, 2004; 42: 1132-1139.
20. Fahim MR, Halim SM, Kamel I. Tumor necrosis factor with acute myocardial infarction. Egypt J Immunol, 2004; 11: 31-37.
21. Halawa B, Salomon P, Jołda-Mydłowska B et al. TNF alpha and IL-6 serum concentration in patients with acute myocardial infarction. Pol Arch Med Wewn, 1999; 101: 197-203.
22. Balbay Y, Tikiz H, Baptiste RJ et al. Circulating IL-1 beta, IL-6, TNF alpha and soluble ICAM-1 in patients witch chronic stable angina and myocardial infarction. Angiology, 2001; 52: 109-114.
23. Vasa M, Fichtlscherer S, Adler K et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation, 2001; 103: 2885-2890.
24. Kobusiak-Prokopowicz M, Orzeszko J, Mazur G et al. Myocardial infarction. MCP-1, MIP-1 alpha and RANTES serum concentration. Kardiol Pol, 2005; 62: 309-316.
25. Xu ZM, Zhao SP, Li QZ, Nie S, Zhou HN. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin Chim Acta, 2003; 338: 17-24.
26. Patti G, Chello M, Pasceri V et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention. Results from ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol, 2006; 48: 1560-1566
27. Briel M, Schwartz GG, Thompson PL et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: A meta-analysis of randomized controlled trials. JAMA, 2006; 295: 2046-2056.